| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
PKC-theta inhibitor 1 manufacturers
|
| | PKC-theta inhibitor 1 Basic information |
| Product Name: | PKC-theta inhibitor 1 | | Synonyms: | PKC-theta inhibitor 1;3-Oxetanemethanamine, 3-[3-[3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]-;PKCtheta inhibitor 1,PKC theta inhibitor 1;PKCθ inhibitor 22 | | CAS: | 1160501-81-4 | | MF: | C17H15F3N4O | | MW: | 348.32 | | EINECS: | | | Product Categories: | | | Mol File: | 1160501-81-4.mol |  |
| | PKC-theta inhibitor 1 Chemical Properties |
| Boiling point | 444.7±55.0 °C(Predicted) | | density | 1.52±0.1 g/cm3(Predicted) | | pka | 9.65±0.29(Predicted) | | form | Solid | | color | White to off-white |
| | PKC-theta inhibitor 1 Usage And Synthesis |
| Uses | PKC-theta inhibitor 1 is the PKCθ inhibitor with an Ki value of 6 nM, inhibits IL-2 production in vivo with an IC50 of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis[1]. | | IC 50 | PKCθ: 6 nM (Ki); PKCδ: 392 μM (Ki); PKCα: 1020 μM (Ki); IL-2 production: 0.19 μM (IC50) | | References | [1] Collier PN, et al. Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. ACS Med Chem Lett. 2019 Jun 27;10(8):1134-1139. DOI:10.1021/acsmedchemlett.9b00134 |
| | PKC-theta inhibitor 1 Preparation Products And Raw materials |
|